Scancell Funding: How Much Did They Raise & Key Investors

How Much Did Scancell Raise?
Funding & Key Investors

Scancell has successfully secured a major strategic investment, bringing its total capital accumulation to $19.6M. This latest infusion of $11.8M underscores the market confidence in the company's proprietary therapeutic vaccine pipeline. By leveraging its unique ImmunoBody technology, Scancell is positioning itself at the forefront of oncology innovation, transitioning from early-stage research into critical clinical validation phases.

The recent financing round, finalized on August 11, 2020, reflects a robust commitment from institutional backers to accelerate the development of SCIB1 and other pipeline assets. This capital injection provides the necessary runway to advance clinical trials and refine the delivery mechanisms of their dendritic cell-targeting vaccines, marking a pivotal moment in the firm's growth trajectory.

What is Scancell?

Scancell

Business Services

Research & Development

Scancell is a clinical-stage biopharmaceutical company specializing in the development of novel therapeutic vaccines for cancer and chronic infectious diseases. At the core of its operations is the ImmunoBody technology platform, a proprietary system designed to overcome the limitations of traditional cancer vaccines. Unlike conventional approaches that require expensive and time-consuming ex vivo dendritic cell manipulation, Scancell’s engineered antibodies target dendritic cells in vivo. This approach effectively stimulates both helper cell and cytotoxic T-lymphocyte responses, providing a scalable and potent alternative for treating melanoma and other tumor types. The platform's versatility extends to potential applications in managing hepatitis and HIV, positioning Scancell as a significant player in the immunotherapy landscape.

How much funding has Scancell raised?

Scancell has raised a total of $19.6M across 2 funding rounds:

2020

Share Placement

$11.8M

Debt

$7.8M

Share Placement (2020): $11.8M with participation from Undisclosed

Debt (2020): $7.9M led by Redmile Funds and Vulpes

Key Investors in Scancell

Redmile Funds

A healthcare-focused investment firm that provides capital to life sciences companies, often participating in late-stage and strategic financing rounds.

Vulpes

An investment management firm with a diverse portfolio, frequently supporting innovative biotech ventures and high-growth technology enterprises.

Undisclosed Investors

What's next for Scancell?

With the recent capital deployment, Scancell is set to prioritize the clinical advancement of its lead candidate, SCIB1, while expanding the utility of the ImmunoBody platform. The strategic focus will likely center on optimizing trial protocols and gathering the longitudinal data required for regulatory milestones. As the company moves deeper into the clinical phase, the emphasis will shift toward demonstrating the efficacy of its non-toxic, targeted vaccination approach in human subjects. Investors will be closely monitoring the progression of these trials, as successful outcomes could validate the ImmunoBody platform as a foundational technology for next-generation oncology therapeutics.

See full Scancell company page

See More Financial Insights